2 June 2021

Valentina Palacio-CastaƱeda, theme Nanomedicine and colleagues, published in Cancers about a hybrid in silico and tumor-on-a-chip approach to model targeted protein behavior in 3D microenvironments.

Engineered proteins possess a great therapeutic potential, but their development as novel therapeutics is impeded by the lack of in vitro models that accurately mimic human physiology. Furthermore, it is often challenging to extrapolate results from animal models to the human situation, and there is an increasing societal pressure to investigate alternatives for animal research due to ethical concerns.

In a study conducted by Wouter Verdurmen, assistant professor, and PhD candidate Valentina Palacio-CastaƱeda from the Department of Biochemistry, in collaboration with researchers from the Institut Curie in Paris, an alternative approach to study therapeutic protein behavior and delivery in complex 3D microenvironments was developed. The research was published on May 18th in the special issue Cancer-on-a-Chip: Applications and Challenges from the journal Cancers.

The study employed a hybrid approach combining mathematical modeling with 3D in vitro models, including tumor spheroids and a tumor-on-a-chip device. Mathematical modeling was utilized to simulate the delivery of engineered therapeutic proteins targeting cancer cells and to predict the biological activity. By cross-comparing simulated and experimental data from 3D models, the researchers were able to correctly predict the best dose needed to deliver therapeutic proteins for eradication of tumor cells, while leaving the surrounding non-tumor cells untouched. This study shows the potential of combining computational approaches with novel in vitro models to advance the development of protein therapeutics. The group of Verdurmen focuses on investigating cytosolic delivery of engineered proteins targeted to specific cell surface receptors and uses different in vitro 3D and organ-on-a-chip platforms and in silico studies that aid in the rational development of a next generation of protein therapeutics.

read more

  • Want to know more about these subjects? Click on the buttons below for more news.


Related news items

Dutch-Nordic Alliance for Precision Cancer Medicine launched

26 November 2021

The Nordic countries (Denmark, Sweden, Norway, and Finland) are together setting up national clinical precision cancer trials modelled on the very successful DRUP trial in the Netherlands.

read more

Last chance - Call for nominations Supervisor of the Year & Image award

25 November 2021

The RIMLS PhD Council has extended the deadline to 1 December to nominate supervisors and images for the supervisor of the year and image awards. Send in your nominations while you still can!

read more

The effects of dopamine levels on reward responsivity

25 November 2021

To adapt to the ever-changing context in which we live, we are constantly deciding how much effort to put into performing our behavior, or how fast to perform our actions. How do people decide how fast to act and how does the brain compute this? Our researchers set out to investigate this.

read more

Looking back at our successful New Frontiers Symposium on Translational Glycoscience

24 November 2021

The impact of Glycoscience for future personalized medicine

read more

RIMLS PhD retreat - review organized during New Frontiers 2021

23 November 2021

This year's RIMLS PhD retreat 2021 was an online event, combined with the New Frontiers symposium. Organized by and for RIMLS PhD candidates, the retreat was again received with great enthusiasm of the attendees.

read more